Replies to post #396959 on NorthWest Biotherapeutics Inc (NWBO)

[X Master]

Gus, It’s an academic leak.

[Mionaer1]

Wow. Could be a leak....

[marzan]

Thanks ATL, as usual a great find from you. The board is indebted to you.

[Flexroy]

Great article reiterates that about 100 people are living on average of 6 years from the study (27% of the group studied) also clarifies CAR-T therapy which I know some people were pumping but seems limited in comparison to DCVAX

[pqr]

Thanks!! ATL

[Doc logic]

ATLnsider,

Thanks for sharing this. One of the key takeaways from this article mentions but does not directly point to what NWBO learned long ago about the importance of controlling macrophage signaling because of their ability to be recruited to either side of the fight.
NWBO has found ways to overcome macrophage recruitment to the dark side of improper immune response in many cases. This is key to understanding proper regulation of immune response to cancer because a therapy is not much good if it can not stop a flood but only hold it off for a short time because critical targets need to be constantly monitored for and eliminated properly with ongoing surveillance after any initial response. NWBO knows how to maintain proper signaling now so that immune response is not interrupted until the job is done in many cases and this will lead to immune memory. These are the long term survivors being seen in the long tail in this trial and in cases outside of this trial like Kat and Mr. Powers.
Any treatment that does not lead to long term immune memory is limited and less than ideal unless the goal is create dependency on the treatment which seems to be the goal of way too many and may explain to some degree the emphasis in research on finding single critical targets. Best wishes.